Canaccord Genuity Group Issues Positive Forecast for Diaceutics (LON:DXRX) Stock Price

Diaceutics (LON:DXRX) had its price target increased by equities research analysts at Canaccord Genuity Group from GBX 215 to GBX 216 in a research report issued on Thursday,Digital Look reports. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 42.29% from the company’s current price.

Diaceutics Trading Down 0.8%

LON:DXRX opened at GBX 151.80 on Thursday. Diaceutics has a one year low of GBX 112.25 and a one year high of GBX 180. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. The firm has a market capitalization of £128.47 million, a price-to-earnings ratio of -84.33 and a beta of 0.92. The business has a fifty day moving average price of GBX 161.50 and a 200-day moving average price of GBX 153.70.

Diaceutics (LON:DXRX) last posted its quarterly earnings results on Tuesday, May 26th. The company reported GBX 11 EPS for the quarter. The business had revenue of GBX 3,844 million for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. Sell-side analysts forecast that Diaceutics will post 1.0107919 EPS for the current year.

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.